AstraZeneca and Daiichi Sankyo win FDA approval for Enhertu combo as new standard in HER2 mBC

AstraZeneca and Daiichi Sankyo have secured U.S. Food and Drug Administration approval for Enhertu (trastuzumab deruxtecan) in combination with pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive breast cancer. The approval is based on the DESTINY-Breast09 Phase III trial, where the combination cut the risk of disease progression or death by 44% compared to the long-standing THP (taxane + trastuzumab + pertuzumab) regimen.

This marks the first newly approved first-line regimen for HER2-positive metastatic breast cancer in more than a decade, signaling a potential shift in standard of care and positioning Enhertu as a new anchor therapy in one of oncology’s most competitive treatment segments.

How does Enhertu plus pertuzumab reshape the first-line HER2-positive mBC treatment paradigm?

The data from the DESTINY-Breast09 trial show a median progression-free survival (PFS) of 40.7 months for Enhertu plus pertuzumab, versus 26.9 months for THP. This substantial improvement not only crossed statistical significance with a hazard ratio of 0.56 but also set a new benchmark in terms of duration without disease progression in a setting where most patients typically progress within two years on standard THP.

Importantly, Enhertu plus pertuzumab becomes the only first-line HER2-positive metastatic breast cancer treatment to outperform THP, a regimen that has remained dominant for over ten years. This directly challenges current treatment sequencing strategies and could displace entrenched standards across academic and community oncology practices in the U.S.

The updated safety data reported no new concerns, and the toxicity profile aligned with previously known risks of each drug. Given that Enhertu had previously demonstrated efficacy in second-line and later settings (DESTINY-Breast03, -04, -06), this first-line positioning allows AstraZeneca and Daiichi Sankyo to solidify lifecycle management for the drug across the metastatic spectrum.

What is the commercial upside and strategic intent behind the Enhertu expansion?

AstraZeneca’s goal is clear: move Enhertu as early in the treatment line as possible to maximize market penetration, clinical exposure, and duration of use. First-line approvals not only improve drug utilization but typically command higher pricing power and stronger access within reimbursement frameworks.

Following the approval, AstraZeneca is obligated to pay Daiichi Sankyo a milestone of $150 million, reflecting commercial rights arrangements in the companies’ 2019 collaboration agreement. U.S. sales of Enhertu are recognized by Daiichi Sankyo, which controls manufacturing and supply. With approximately 10,000 patients in the U.S. treated annually in the first-line HER2-positive mBC setting, the commercial runway is significant—particularly given that up to 30% of patients do not receive treatment after disease progression on first-line therapy.

For Daiichi Sankyo, this first-line approval represents a critical validation of its DXd antibody-drug conjugate (ADC) technology, which underpins not just Enhertu but its broader ADC portfolio including datopotamab deruxtecan (Datroway). Regulatory momentum in the U.S. could catalyze global expansion efforts already underway via Project Orbis, which is currently reviewing this indication in Switzerland and Singapore.

How does this change the competitive landscape for HER2-targeted therapies?

The HER2-positive mBC space is already crowded with high-performing regimens across lines of therapy. The first-line space, until now, had been relatively static, with THP as the de facto standard. Enhertu’s first-line entry represents a paradigm shift and introduces high-pressure dynamics for other HER2-targeted brands.

Roche, whose HER2 franchise has long benefited from the durability of trastuzumab and pertuzumab, now faces headwinds. If Enhertu plus pertuzumab becomes the new clinical default, sales erosion for THP could be swift, particularly in markets where Enhertu has already been adopted in later lines.

The clinical implications also affect future development strategies for newer HER2 agents. Ongoing efforts to bring in novel bispecifics, HER2-targeted T-cell engagers, and combination therapies may now need to be restructured around Enhertu-containing regimens. Additionally, physicians may need to reconsider whether to reserve Enhertu for later lines or front-load its use for eligible patients.

What regulatory pathways and global expansion mechanisms are in play?

The approval benefitted from two key FDA acceleration initiatives: Priority Review and the Real-Time Oncology Review (RTOR), designed to compress timelines for high-impact oncology drugs. Furthermore, this application was processed under Project Orbis, a collaborative global review mechanism involving agencies like Swissmedic and Singapore’s HSA. Regulatory submissions are also underway in other regions.

This accelerative regulatory strategy is now becoming a hallmark of high-performing oncology pipelines. Enhertu’s journey from second-line approval to first-line in under six years reflects both trial design efficiency and a well-orchestrated regulatory engagement approach.

If other health authorities follow the FDA’s lead, Enhertu plus pertuzumab could become a globally harmonized first-line standard by mid-2026, contingent on safety, pricing, and access negotiations in key markets.

Why does this approval reflect a broader ADC momentum across oncology?

Enhertu is the most clinically advanced program in both AstraZeneca’s and Daiichi Sankyo’s antibody-drug conjugate portfolios. Its success is emblematic of a larger ADC renaissance that spans multiple indications, including HER2-low breast cancer, non-small cell lung cancer, and gastric cancer. Enhertu already has approvals across seven indications and more than 90 countries, with ongoing trials in solid tumors and hormone receptor–positive HER2-low subtypes.

The DESTINY-Breast09 approval sets the stage for future ADC approvals to target earlier treatment lines, multi-drug combination regimens, and potential basket indications. With pharma majors now accelerating ADC dealmaking, AstraZeneca’s Enhertu franchise may serve as a bellwether for how ADCs are integrated into frontline oncology pathways going forward.

What are the risks that could still affect Enhertu’s first-line adoption and growth?

Despite its clinical success, Enhertu’s long-term adoption in the first-line setting depends on a number of practical and economic factors. Its safety profile, although manageable, includes risks such as interstitial lung disease (ILD), which requires monitoring and specialist management. Broad-based adoption in non-academic settings may be uneven without robust education and support infrastructure.

Payer behavior will also be critical. Enhertu carries a high list price, and cost-effectiveness thresholds will likely be tested in both U.S. commercial plans and public reimbursement agencies abroad. Institutions may take a cautious approach until real-world outcomes confirm the trial results.

Finally, Enhertu’s movement into the first-line setting compresses the window for second-line therapy, raising new sequencing challenges for clinicians. It remains unclear how Enhertu retreatment or sequencing will play out in patients who progress on first-line therapy.

What are the key takeaways from the Enhertu plus pertuzumab approval in first-line HER2-positive mBC?

• Enhertu plus pertuzumab is the first new first-line treatment for HER2-positive metastatic breast cancer approved in over a decade.

• DESTINY-Breast09 data show a 44% risk reduction in disease progression or death versus THP, with median PFS extended to over 40 months.

• AstraZeneca and Daiichi Sankyo will likely benefit from expanded duration of therapy, earlier market positioning, and deeper clinical integration.

• The approval reinforces the commercial viability and clinical utility of Daiichi Sankyo’s DXd ADC platform across multiple tumor types.

• Roche’s HER2 franchise, particularly the standard THP regimen, may lose share unless adjusted or repositioned in new lines.

• U.S. regulatory acceleration mechanisms such as RTOR and Project Orbis enabled rapid approval and global expansion runway.

• Cost, safety management, and real-world outcomes will shape payer decisions and provider uptake in diverse clinical settings.

• Enhertu’s lifecycle strategy is now a case study in how ADCs can expand across indications, lines of therapy, and global geographies.